Overview

Research in Severe Asthma (RISA) Trial

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of the Alair System for the treatment of severe refractory asthma. This will be a multicenter, randomized controlled study comparing the effects of treatment with the Alair System to standard drug therapy in patients with severe asthma refractory to standard medication therapy. A total of 30 subjects will be randomized 1:1 to the Alair Group (Medical management + Alair Treatment) OR the Control Group (Medical management only).
Phase:
N/A
Details
Lead Sponsor:
Asthmatx, Inc.
Boston Scientific Corporation